Toceranib

Source: Wikipedia, the free encyclopedia.
Toceranib
Ball-and-stick model of the toceranib molecule
Clinical data
Trade namesPalladia
AHFS/Drugs.comVeterinary Use
License data
Antineoplastic agent
ATCvet code
Legal status
Legal status
Pharmacokinetic data
Bioavailability77%
Protein binding91%-93%
Elimination half-life16 h
Identifiers
  • 5-[(5Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
JSmol)
  • Fc1ccc2c(c1)/C(C(=O)N2)=C/c4c(c(C(=O)NCCN3CCCC3)c([nH]4)C)C
  • InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-
  • Key:SRSGVKWWVXWSJT-ATVHPVEESA-N

Toceranib is a

kit tyrosine kinase, though it may also have an anti-angiogenic
effect.

References

  1. PMID 19470739
    .
  2. ^ CBS News FDA Approves First-Ever Dog Cancer Drug
  3. ^ "FDA: First Drug to Treat Cancer in Dogs Approved". U.S. Food and Drug Administration (FDA) (Press release). 3 June 2009. Archived from the original on 22 July 2010. Retrieved 2 October 2021.
  4. ^ "Palladia New Animal Drug Application" (PDF). U.S. Food and Drug Administration (FDA). 22 May 2009. Archived from the original (PDF) on 16 November 2010. Retrieved 2 October 2021.
  5. ^ "In Trials for New Cancer Drugs, Family Pets Are Benefiting, Too". The New York Times. 24 November 2006. Retrieved 2 October 2021.

External links

  • "Toceranib". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Toceranib&oldid=1190950121"